News and Trends 20 Oct 2022 Sunshine Biopharma acquires Nora Pharma Sunshine Biopharma Inc, a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. Nora Pharma is now a wholly owned subsidiary of Sunshine Biopharma Inc. The addition of Nora Pharma allows Sunshine Biopharma to expand […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 AbbVie acquires LifeArc portfolio company DJS Antibodies AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Ophthalmology biopharma company Oculis combines with EBAC Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care and European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC), have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named Oculis Holding SA and will work to accelerate the development […] October 17, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Ginkgo Bioworks acquires Altar and Circularis Ginkgo Bioworks has announced the acquisition of two biotech companies, Altar, a French firm with a proprietary adaptive evolution platform, and Circularis, which has a proprietary circular RNA and promoter screening platform. Altar acquisition A fleet of Altar’s automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo’s Foundry to serve customers across food and […] October 4, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Estrella and TradeUP merge to become publicly traded company Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed Estrella Immunopharma, Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics LogicBio Therapeutics, Inc. has entered into a definitive agreement under which Alexion, AstraZeneca Rare Disease (Alexion) will acquire LogicBio. The proposed acquisition brings LogicBio’s technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion’s growth in genomic medicines. Fred Chereau, president and chief executive officer at LogicBio, said: “We are excited […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. The deal could eventually be worth upwards of $1.4 billion. Its lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 AmplifyBio acquires PACT Pharma assets AmplifyBio has acquired select assets from PACT Pharma, Inc., a privately held biopharmaceutical company developing neoantigen-specific T cell receptor cell therapies. The deal will provide AmplifyBio with advanced characterization platforms, bioinformatics capabilities, and 40 drug development experts to enhance its own cell and gene therapy service offerings. AmplifyBio will also acquire the South San Francisco […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 GENFIT to acquire Versantis to expand liver disease portfolio GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. GENFIT said the acquisition fits its strategic vision of becoming a global leader in ACLF (acute-on-chronic […] September 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis BioTherapeutics will acquire the outstanding shares of Ducentis for an upfront cash payment of approximately $16 million and Arcutis stock valued at approximately $14 million, […] September 8, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Lesaffre acquires genome editing company Recombia Biosciences Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Evotec SE acquires highly-flexible drug manufacturing space for €1 A clinical and commercial manufacturing platform for small molecule therapeutics has expanded following an acquisition signed for. Evotec SE made the announcement today (August 25) after signing the contract yesterday for €1 to take Central Glass Germany GmbH from Japanese manufacturing company Central Glass Co. Ltd. It will now operate as Evotec Drug Substance (Germany) […] August 25, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email